During viral infection, pattern recognition receptors (PRRs) and their associated adaptors recruit TANK-22 binding kinase 1 (TBK1) to activate interferon regulatory factor 3 (IRF3), resulting in production of type I 23 interferons (IFNs). ICP0 and ICP34.5 are amongst the proteins encoded by herpes simplex virus 1 (HSV-1) 24 that modulate type I IFN signaling. We constructed a recombinant virus (∆XX) which lacks amino acids 25 87 -106, a portion of the previously described TBK1-binding domain of the γ34.5 gene (D. Verpooten, Y.
INTRODUCTION 51
The neurotropic herpes simplex virus 1 (HSV-1) causes recurring mucosal lesions and is persistent 52 throughout the life of its host (1) . Following infection of mucosal membranes, the virus travels in a 53 retrograde direction in axons of the peripheral nervous system to establish latency in the neuronal cell 54 bodies which reside in sensory ganglia (2-4). Spontaneous reactivation can occur resulting in 55 anterograde shuttling of reactivated virus back to mucosal membranes where lytic replication may 56 reoccur, facilitating host-to-host transmission. During HSV-1 replication, the innate immune response is 57 triggered through sensors such as toll-like receptors (TLRs) and pattern recognition receptors (PRRs) (5, 58 6). Downstream adaptors may activate TANK-binding kinase 1 (TBK1) which phosphorylates and 59 activates the transcription factor interferon regulatory factor 3 (IRF3) (7, 8) . Phosphorylated IRF3 forms 60 a homodimer which translocates to the nucleus and upregulates transcription of type I interferons (IFNs) 61 and IFN-stimulated genes (ISGs) by binding to interferon-stimulated response element (ISRE) promoters 62 addition, viral dsRNA triggers dsRNA-dependent protein kinase (PKR) to phosphorylate and inactivate 67 eukaryotic initiation factor 2 alpha (eIF2α), leading to translational arrest and furthering the antiviral 68 state of the cell (13, 14) . 69
Herpesviruses encode many functions that help the virus to evade or manipulate the host immune 70 system. Since IRF3 is a crucial factor in initiating the IFN response, HSV-1 has evolved redundant 71 pathways to target this molecule. Notably, the E3-like ubiquitin ligase infected cell protein 0 (ICP0), 72
encoded by the HSV-1 immediate early gene α0, facilitates degradation of IRF3 and IRF7 though its RING 73 finger domain (15, 16) . Additionally, the Ser/Thr kinase, Us3, prevents IRF3 activation and thereby 74 inhibits IFN-β production (17). Overexpression of the leaky-late gene, γ34.5, results in binding of ICP34.5 75 to TBK1, leading to TBK1 degradation and disruption of IRF3 and TBK1 interaction (18) . This interaction 76 was shown to require amino acids 72 -106 of ICP34.5. In addition, a recombinant HSV-1 strain lacking 77 the first 147 amino acids of ICP34.5 fails to prevent IRF3 phosphorylation and is significantly attenuated 78 in corneal infections (19). However, this N-terminal deletion mutant also lacks the 19 amino acid region 79 required to bind the autophagy related protein, beclin1 (20). Amino acids 68 -87 of ICP34.5, known as 80 the beclin1-binding domain (BBD), is essential for inhibiting beclin1-mediated macroautophagy (21-23). 81
Viruses lacking this domain exhibit reduced viral replication in neuronal tissues, attenuated virulence 82 following intracerebral (i.c.) infection, and heightened adaptive immune responses. Separating the roles 83 of these domains in the disruption of the IFN response and autophagy during pathogenesis is crucial for 84 a better understanding of γ34.5, a pivotal virulence factor in humans and mice (24-28). 85
The HSV-1 ICP34.5 protein consists of 248 amino acids with a disordered N-terminal region followed by a 86
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Membrane was blocked with either 5% bovine serum albumin in TBS with 0.1% polysorbate 20 (TBST; 165 Alfa Aesar) for phosphorylation-specific protein detection or 5% non-fat milk in PBS with 0.1% 166 polysorbate 20 (PBST) for all others. Primary and secondary antibody incubations were done in blocking 167 buffer for 18 h at 4°C and 1 h at room temperature, respectively. Primary antibodies used were mouse 168 anti-HA.11 (16B12; BioLegend), mouse anti-p32 (11874-mm04; Sino Biologicals), rabbit anti-ICP34. have been previously described to bind ICP34.5 to the host antiviral factor, TBK1 (18) . In order to 192 evaluate the importance of this region further, we used expression constructs and recombinant viruses 193 lacking portions of this domain (Fig. 1A) . The ΔXX mutant lacks amino acids 87 -106, which is outside of 194 the region where the TBD overlaps the BBD. The ΔBX mutant lacks both domains. First, we investigated 195 the impact of the domain deletions on the ability of ICP34.5 to bind beclin1 by co-immunoprecipitation 196 of overexpressed ICP34.5 variants with endogenous beclin1 (Fig. 1B) . As expected, expression of 197 pΔBX(17)-HA and pΔBBD(17)-HA, which both lack the beclin1-binding domain, failed to bind beclin1. 198
However, pΔXX(17)-HA bound beclin1, suggesting that this region is dispensable for interaction with 199 beclin1 and inhibition of beclin1-mediated autophagy. Next, we assessed the ability of wildtype and 200 mutant ICP34.5 to bind endogenous TBK1. Unexpectedly, even full-length ICP34.5 failed to bind 201 endogenous TBK1 either by co-immunoprecipitation (Fig 1C) , or by mass spectrometry approaches (data 202 not shown). As additional controls, we stained for p32, which binds ICP34.5 (53). As expected, all forms 203 of ICP34.5 tested bound endogenous p32 ( ICP34.5 and TBK1 were performed using constructs of ICP34.5 from the background of HSV-1 strain F. 208
We wished to address the caveat that the interaction of ICP34.5 with TBK1 might be strain-specific by 209 analyzing ICP34.5 constructs generated from both strains F and 17. We observed that overexpressed 210 ICP34.5 from either strain bound overexpressed TBK1 (Fig. 1D ). However, we were unable to detect an 211 interaction between ICP34.5 and endogenous TBK1, regardless of strain. These results indicate that 212 while ICP34.5 bound to its expected partners, it failed to bind endogenous TBK1. Furthermore, binding 213 was only detected if both ICP34.5 and TBK1 proteins were exogenously overexpressed in the cell, as 214
shown here and previously (18) . Nonetheless, the observed binding of overexpressed protein did occur 215 in both strain F and 17, prompting us to further evaluate the biological relevance of this interaction 216 during HSV-1 infection. 217
IRF3 activation and translocation is unaffected by the beclin1-or TBK1-binding domains. Upon 218
association with TANK, TBK1 phosphorylates IRF3 at serine residue 396 (54-56). Activated IRF3 then 219 forms a homodimer and localizes to the nucleus to upregulate ISGs (56). We wished to further test the 220 hypothesis that IRF3 activation is regulated via the TBK1-binding domain. We treated primary HFF cells 221 with IFN-β, infected with wildtype, mutant HSV-1, or mock and examined cells for IRF3 nuclear 222 localization by immunofluorescence ( Fig. 2A and B) . Ten hours after infection with Δ0 and Δ34.5, we 223 observed 25% and 10% of cells with nuclear translocation of IRF3, respectively (Fig. 2B) . In contrast, 224 levels of nuclear IRF3 in cultures infected with ΔBBD and ΔXX were low (~2% of cells) and comparable to 225 wildtype strain 17. In addition, we used western blot to evaluate IRF3 phosphorylation with a phospho-226 specifc antibody to Serine 396 (Fig. 2C) . Similarly, we observed heightened IRF3 phosphorylation in 227 extracts of cells infected with Δ0 and Δ34. The TBK1-binding domain is not important for viral replication or virulence. In order to assess the role 232 of amino acids 87 -106 of ICP34.5 on viral replication, we infected primary HFF cells that were pre-233 treated with IFN-β (Fig. 3A) . Replication of Δ34.5 was comparable to control virus in untreated cells but 234 was significantly reduced (p<0.001) with IFN-β pre-treatment relative to control virus, consistent with 235 other studies (39, 57). In contrast, ΔXX replicated comparably to marker-rescued virus (∆XX-R) 236 regardless of IFN-β pre-treatment. Additionally, a multi-step growth curve was performed comparing 237 ∆XX-R and wildtype strain 17 with or without IFN-β pre-treatment and no differences in virus replication 238 were observed (data not shown). To assess replication in vivo, we measured ΔBBD and ΔXX replication in 239 a variety of tissues following corneal infection of mice relative to marker-rescued virus. All three viruses 240 replicated comparably in corneas (tear film), periocular skin, trigeminal ganglia, and brain (Fig. 3B) . To 241 assess the importance of amino acids 87 -106 to the neurovirulence function of ICP34.5, we examined 242 time to reaching endpoint criteria following intracerebral infection (Fig. 3C ). As expected, low mortality 243 was observed following ΔBBD and Δ34.5 infections. In contrast, and similar to wildtype virus, ΔXX 244 infection caused 60 percent of mice to reach endpoint criteria by day 7 post infection. These data 245 suggest that amino acids 87 -106 do not play a role in the modulating replication in vitro, replication in 246 vivo, or neurovirulence. 247
The BBD (amino acids 68 -87) is necessary to bind TBK1 in overexpression conditions. Previous studies 248
showed that residues 72 -106 were responsible for binding TBK1 (18) . In this study, overexpression of 249 ICP34.5 and TBK1 was required to demonstrate their interaction (Fig. 1) . In addition, ΔXX replicated 250 comparably to wildtype virus and retained the ability to control IRF3 (Fig. 2 and 3) . In light of these data, 251
we wished to further define the TBK1-binding region using overexpression of TBK1 and the ICP34. variants, followed by immunoprecipitation of ICP34.5 (Fig. 4) . We recapitulated the finding that full-253 length ICP34.5 bound to TBK1 only when TBK1 was overexpressed (lanes 1 and 5) . When co-expressed 254 with TBK1, ΔBX and ΔBBD failed to bind TBK1 (lanes 2 and 3) . Unexpectedly, ΔXX was still able to bind 255 overexpressed TBK1 (lane 4). Together, these results show that the region required to bind TBK1 and 256 beclin1 fully overlap. Residues 87 -106 of ICP34.5 are therefore dispensable for interaction with TBK1. 257
Maintenance of ICP0 expression is dependent on ICP34.5. In agreement with previous data (18, 19) , it 258 was apparent that infection with Δ34.5 induced hyperphosphorylation of IRF3 (Fig. 2C ). This led us to 259 hypothesize that the inability of Δ34.5 to control IRF3 activity was due to inefficient translation of viral 260 factors that modulate the IFN response and IRF3. First, we examined the abilities of our mutant viruses 261 to block translational shutoff by measuring eIF2α phosphorylation in HFF cells (Fig. 5A) . As expected, 262 Δ34.5 infection induced high levels of phosphorylated eIF2α. In contrast, Δ0, ΔBBD, ΔXX, and wild type 263 strain 17 all maintained low levels of phosphorylated eIF2α, consistent with modulation of translational 264 arrest. Next, we assessed a panel of HSV-1 proteins by quantifying mean fluorescence intensity/cell 265 (MFI) using immunofluorescence to determine whether ICP34.5 is required to maintain their expression 266 (Fig. 5B) . Interestingly, the two immediate early genes tested, ICP0 and ICP4, showed a significant 267 decrease in intensity in Δ34.5 infections when compared to control. These findings by IF were 268 recapitulated using western blotting which showed that ICP0 was under-expressed by Δ34.5 relative to 269 strain 17 when normalized to β-actin (Fig. 5C) . Interestingly, the expression of ICP8 (early gene), gC and 270 ICP5 (late genes) by ∆34.5 were comparable to strain 17 ( Fig. 5B and 5C ). In addition, expression of VP16 271 was not dependent on ICP34.5 ( Fig. 5B and 5C ), which suggested that changes in ICP0 and ICP4 were not 272 due to alterations in transcription. The immediate early protein, ICP0, plays a crucial role in controlling 273 the innate immune response by inhibiting IRF3 and preventing activation of IFN and ISGs (16, 58, 59). To 274 further confirm the observation that ICP34.5 is required for the maintenance of ICP0 expression, we 275 measured ICP0 by immunofluorescence using MFI in HFFs and primary TG neurons in culture (Fig. 5D-F) . When compared to wildtype virus, we observed a significant reduction in ICP0-specific MFI at 10 hours 277 after infection with Δ34.5 in HFF cells relative to strain 17 ( Fig. 5D and 5E ). In HFF cells infected with 278 strain 17, expression of ICP34.5 is detectable at 3 hpi and peaks around 6 hpi (data not shown). Both 279 Us11 and ICP34.5, which contribute to countering translational arrest, are present in the tegument (60). 280
Despite this, we speculate that de novo ICP34.5 is required for the maintenance of ICP0 expression, and 281 other viral genes throughout infection. Therefore, in the absence of ICP34.5, we do not observe a deficit 282 in ICP0 until peak ICP34.5 expression and activity occur (6 hpi and onward). Similarly, a significant 283 difference in ICP0 expression was observed in TG neurons at 10 hpi and MOI 1000 (Fig. 5F ) and at 24 hpi 284 and MOI 25 (data not shown). Finally, we wished to address the hypothesis that the inability of Δ34.5 to 285 reverse translational arrest was responsible for the loss of ICP0 expression. If so, restoration of ICP0 286 expression in the absence of γ34.5 should restore the ability of HSV-1 to antagonize IRF3. To test this 287 hypothesis, we used SUP1 (35, 43), an HSV-1 mutant which lacks ICP34.5 but due to altered kinetics of 288 Us11 expression, shows normalized HSV-1 translation during infection (Fig. 5G) . We showed that where 289 the virus was unable to fully express ICP0 (either reduced as in Δ34.5, or absent as in Δ0) it was unable 290 to control IRF3 phosphorylation (lanes 1 and 2) relative to wild-type strain 17 (lane 3). In contrast, when 291 ICP0 expression is restored to wildtype levels (SUP1 and its wild type control, Patton), IRF3 292 phosphorylation is prevented in both the presence and absence of ICP34.5 (lanes 4 and 5). These results 293
show that viral modulation of translational arrest is crucial for sustaining expression of certain HSV-1 294 immediate early genes throughout infection in order to regulate key aspects of the antiviral response. The neurovirulence factor ICP34.5 of HSV-1 is a multifunctional protein responsible for reversal of 299 translational shutoff, inhibition of autophagy, and facilitation of nuclear egress (20, 32, 53). Using over-300 expression approaches, previous studies have defined residues 72 -106 of ICP34.5 to be important for 301 inhibiting innate antiviral responses mediated by TBK1 (18) . Furthermore, a virus lacking 147 amino 302 acids from the N-terminus of ICP34.5 failed to control TBK1-dependent interferon responses (18, 19) . 303 this study, which tested directly whether residues 87 -106 are able to modulate TBK1. 313
As expected, we showed wild type ICP34.5 bound endogenous beclin1, p32, PP1α, and eIF2α. 314
Importantly, these binding interactions were all maintained in the context of the ΔXX mutation. In 315 addition, we have recapitulated the previously reported interaction between full-length ICP34.5 and 316 TBK1 following overexpression of both proteins. The TBK1/ICP34.5 binding was observed in both strain 317 F, as previously reported (18), and strain 17. We were unable, however, to detect binding of 318 endogenous TBK1 with expression of any ICP34.5 variant. It was possible that our immunoprecipitation 319 assays lacked sufficient sensitivity to detect this interaction without overexpression of TBK1, providing 320 further rationale to create ΔXX and examine its phenotype in vitro and in vivo. 
